Denali Therapeutics Inc. (NASDAQ: DNLI) announced that results from a Phase 1/2 clinical trial of its investigational treatment tividenofusp alfa ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE